Michael Lietz

Philip Morris International (Switzerland)

Papers

1

Total Citations

52

H-Index

1

About

Michael Lietz is a biomedical researcher whose work centers on the intersection of environmental toxicology and cardiovascular disease, with a particular focus on how cigarette smoke exposure disrupts lipid metabolism and promotes atherosclerosis. His most-cited study, "Modulation of atherogenic lipidome by cigarette smoke in apolipoprotein E-deficient mice" (2012, 52 citations), provided critical mechanistic insights into how smoking alters the lipidome—the full spectrum of lipids in the body—to drive plaque formation in arteries. By demonstrating that cigarette smoke modifies specific lipid species in a mouse model of atherosclerosis, Lietz helped bridge the gap between environmental risk factors and molecular pathology, offering a foundation for future therapeutic targets. His work has been instrumental in advancing our understanding of how lifestyle factors directly reprogram metabolic pathways, with implications for both basic science and public health interventions. Through this research, Lietz has established himself as a key contributor to the fields of lipidomics and cardiovascular toxicology, earning recognition for his ability to translate complex lipid data into actionable biological insights.

Research Focus

Key Achievements

1
H-Index
1
Papers
52
Total Citations
52
Avg Citations/Paper
🏆 Most Cited Paper
Modulation of atherogenic lipidome by cigarette smoke in apolipoprotein E-deficient mice
52 citations · 2012
📈 Most Prolific Year: 2012 (1 Papers)
🤝 Key Collaborators: 12
🏛 Institutions: Philip Morris International (Switzerland)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago